Countervail Corporation


Countervail receives $981,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity.

Following the successful completion and review of laboratory studies data for the pre-exposure use of AverTox to protect against exposure to lethal levels of soman, sarin and VX, an additional $981,000 in SBIR grant money has been awarded to Countervail. These funds will be used to continue the development of AverTox toward and eventual NDA submission.